Mr. Zhang Junjie (张俊杰), aged 47, is a non-executive Director. He was appointed as a non-executive Director on August 5, 2019 and is mainly responsible for participating in decision-making of important matters of our Group and the high-level oversight of the management and operations of our Group. Mr. Zhang also serves as a director of MP CardioFlow since he joined our Group in October 2017.

Mr. Zhang has over 20 years of experience in the healthcare investment industry. He is currently a non-executive director of Chemclin Diagnostics Co., Ltd. (科美诊断技术股份有限公司), a company listed on the Shanghai Stock Exchange from April 9, 2021 (stock code: 688468) since September 2019 and a non-executive director of Suzhou Nanomicro Technology Company Limited (苏州纳微科技股份有限公司), a company listed on the Shanghai Stock Exchange from June 23, 2021 (stock code: 688690) since November 2019. From July 2018 to November 2023, he served as a director of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (上海微创心脉医疗科技(集团)股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688016).

Prior to joining our Group, Mr. Zhang served as a consultant of Deloitte Consulting (Beijing) Co., Ltd. (德勤咨询(北京)有限公司) from July 2004 to March 2006 and an investment manager of H&Q Asia Pacific Ltd. (汉鼎亚太有限公司) from March 2006 to December 2006. From December 2006 to September 2016, he was as a global partner of Actis (Beijing) Investment Consulting Center (L.P.) (英联(北京)投资咨询中心(有限合伙)) and he has been a founding partner of Huaxing Healthcare Fund (华兴医疗产业基金) since November 2016.

Mr. Zhang received a bachelor’s degree in organic chemistry from Lanzhou University (兰州大学) in China in June 2000 and a master’s degree in management and professional accounting from University of Toronto in Canada in November 2004.